Fig. 8: The chemosensitizing efficacy of LGALS1 inhibitor OTX008 in AML cells and xenograft model.

A, B Western blot analysis of Galectin-1 expression in AML cell line MV-411 (A) and patient Pt#14 (B) after treatment with 30 µM OTX008 for different time points (0, 12, 24, 36, and 48 h). C Colony formation assays of AML cell line THP-1 and MV-411 with or without OTX008 treatment. Quantification of the number of colonies was shown on the right, ***P < 0.001. D CCK-8 assay showing the cell viability of THP-1 and MV-411 cells incubated with DMSO, Cytarabine (200 nm), or Cytarabine (200 nm) + OTX008 (30 µM) for different time points (0, 12, 24, 36, and 48 h). E–G CCK-8 assay showing the cell viability of PBMC from five refractory AML patients during treatment of different strategies for different time points (0, 12, 24, 36, and 48 h). H Scheme showing the process of engrafting human primary AML cells in NCG mice and drug treatment workflow. I The spleen images from mice of different treatment groups. J Spleen weights of NCGs of different treatment groups. P values were calculated by two-tailed t-test. K Representative flow cytometric analysis of the human leukemic burden in bone marrows from NCG mice of different treatment groups. L Quantification of human leukemic burden (hCD45⁺ cells relative to the total cells) in the bone marrow of NCG mice post-treatment of different groups. M Representative flow cytometric analysis of cells with high Galectin-1 expression in hCD45⁺ cells from bone marrows of different treatment groups. N Percentage of cells with high Galectin-1 expression in hCD45⁺ cells from bone marrows of different treatment groups.